AXSM - NASDAQ
Axsome Therapeutics, Inc.
$233.49
+5.1%Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
At a Glance
Live SnapshotAxsome Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Moderate working capital outflow. Typical for growing businesses, but ensure it's supporting revenue growth, not inefficiency.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Axsome Therapeutics, Inc. Cash Flow Statement
AXSM • NASDAQ
| Axsome Therapeutics, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||||||
-183.2M | -287.2M | -239.2M | -187.1M | -130.4M | -102.9M | -68.3M | -31M | -28.9M | -27.2M | -10.6M | -6M | -2.2M | |
9.1M | 8M | 6.8M | 4.4M | 76K | 77.7K | 37.3K | 48.9K | 42.6K | 20.5K | 3.5K | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.2M | 0.0 | -2.8M | 646K | 0.0 | 2.3M | 0.0 | 0.0 | |
93.8M | 0.0 | 62.6M | 37.7M | 20.8M | 14.8M | 6.1M | 1.8M | 2.1M | 2M | 803.3K | 376.8K | 55.3K | |
9.5M | 116.9M | 53.1M | 4.8M | 974K | 8M | 650K | 375.6K | 470.5K | 68.9K | -902.2K | 512.7K | 327.2K | |
-22.5M | 33.9M | -28.4M | 23.7M | 324K | 412K | 15.2M | 1.5M | -759.5K | 3.8M | 937.7K | 514.7K | 153.1K | |
-93.4M | -128.4M | -145.1M | -116.5M | -108.2M | -78.5M | -46.4M | -30.1M | -26.5M | -21.3M | -7.4M | -4.6M | -1.6M | |
INVESTING ACTIVITIES | |||||||||||||
-480K | -270K | -582K | -702K | -308K | -45.9K | -16.1K | -32.7K | -9.9K | -104.6K | -20.2K | (0.0) | (0.0) | |
(0.0) | (0.0) | (0.0) | -53M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-480K | -270K | -582K | -53.7M | -308K | -45.9K | -16.1K | -32.7K | -9.9K | -104.6K | -20.2K | (0.0) | (0.0) | |
FINANCING ACTIVITIES | |||||||||||||
126.3M | 40.8M | 258.8M | 243.8M | 7.4M | 14.1M | 238.2M | 12.9M | 23.7M | 33K | 45.5M | 0.0 | 0.0 | |
-7.8M | -990K | 85M | 45M | 0.0 | 28.3M | 12.8M | -3.3M | -277.8K | 10M | 7.3M | 5.2M | 3.8M | |
-17.1M | 18M | -12.7M | -4.2M | 3.7M | -52.8K | 1.4M | 486K | 484.6K | -64.9K | -12.5K | -62.5K | -58K | |
101.5M | 57.8M | 331M | 284.6M | 11.1M | 42.4M | 252.4M | 10M | 23.9M | 10M | 52.9M | 5.1M | 3.7M | |
CASH FLOW SUMMARY | |||||||||||||
7.6M | -70.8M | 185.4M | 114.4M | -97.4M | -36.1M | 206M | -20.1M | -2.6M | -11.4M | 45.4M | 530K | 2.1M | |
315.4M | 386.2M | 200.8M | 86.5M | 183.9M | 220M | 14M | 34M | 36.6M | 48M | 2.6M | 2.1M | 1.6K | |
322.9M | 315.4M | 386.2M | 200.8M | 86.5M | 183.9M | 220M | 14M | 34M | 36.6M | 48M | 2.6M | 2.1M | |
-93.9M | -128.7M | -145.7M | -117.2M | -108.5M | -78.5M | -46.4M | -30.1M | -26.5M | -21.4M | -7.5M | -4.6M | -1.6M |
SEC Filings
AXSM - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 03, 2026 | June 03, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 04, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 04, 2026 | May 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | April 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 01, 2026 | April 01, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 23, 2026 | February 23, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 23, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 17, 2026 | February 17, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 |
Related Guides
Continue your AXSM research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.